TABLE 4.
Univariable analysis of the association between potential predictor variables and microbiological eradication in patients with MRSA bacteremia
| Variableb | Value for the variablea |
||
|---|---|---|---|
| OR | 95% CI | P value | |
| Treatment group (Combo vs VAN alone) | 5.15 | 1.21–29.7 | 0.026 |
| Age (yr) | 0.99 | 0.95–1.04 | 0.719 |
| LOS (days) | 1.04 | 0.99–1.14 | 0.101 |
| Vancomycin serum level (mg/liter)c | 0.97 | 0.93–1.01 | 0.136 |
| Cancer | 1.24 | 0.24–12.41 | 0.816 |
| Hemodialysis | 0.07 | 0.01–0.33 | <0.001 |
| Immunosuppression | 3.51 | 0.39–465.03 | 0.317 |
| Injection drug use | 4.96 | 0.56–654.41 | 0.178 |
| MRSA colonization | 0.76 | 0.17–4.44 | 0.733 |
| Endocarditis | 1.02 | 0.24–5.88 | 0.985 |
| Osteomyelitis | 4.58 | 0.52–604.59 | 0.206 |
| ICU admission | 0.79 | 0.19–3.67 | 0.753 |
| Ventilator use | 1.46 | 0.29–14.56 | 0.676 |
| Pitt bacteremia score of ≥4 | 1.07 | 0.82–1.69 | 0.653 |
| MRSA strain (USA300 vs USA100) | 2.52 | 0.62–11.67 | 0.197 |
| agr functionality | 1.08 | 0.18–4.77 | 0.920 |
a
The odds ratio (OR) and 95% confidence interval were derived using Firth's penalized maximum likelihood bias reduction approach to logistic regression.
b
LOS, length of stay; ICU, intensive care unit.
c
One patient in each treatment group did not have a vancomycin serum level documented in the electronic medical record. Both patients experienced microbiological eradication.